Companies / ORMP Oramed Pharmaceuticals Inc. (ORMP)
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York, New York.
Ticker ORMP Exchange Nasdaq Sector Healthcare Industry Biotechnology Market cap $160.57M 52-week range $2.09 - $5.47 Valuation Share price $3.86 (close of Nov 6, 2026) Price performance Period Change 1 day -0.77% 5 days -6.08% 1 month -11.87% 3 months -10.23% 6 months -1.53% Year to date +35.44% 1 year +75.45% 3 years +97.95% 5 years -85.61% 10 years -35.67% All time -51.26%
Short interest As of Oct 15, 2026 Short % of float 4.21% Shares short 1.45M Days to cover 10.40 Change since prior report +1.23% Source FINRA consolidated short interest Profitability and growth Return on equity 32.07% Return on invested capital -7.52% Return on assets 27.74% Return on capital employed -7.12% Cash flow and balance sheet Current ratio 4.98x Net debt to EBITDA -0.23x Latest reported year Period end Dec 31, 2025 Fiscal year 2025 EBITDA -$14.97M Net income $64.05M Earnings per share $1.53 Research and development $6.38M Shares outstanding 41.40M Income statement by year Period end Revenue Gross profit Net income EPS 2025-12-31 - - $64.05M $1.53 2024-12-31 - - -$19.06M -$0.48 2023-12-31 $1.34M - $5.09M $0.14 2022-12-31 $2.70M $852.00K -$36.56M -$0.94 2021-08-31 $2.70M - -$22.99M $0.78 2020-08-31 $2.71M - -$11.51M -$0.56 2019-08-31 $2.70M $2.61M -$14.36M -$0.82 2018-08-31 $2.45M - -$12.73M -$0.86 2017-08-31 $2.46M $2.27M -$10.48M -$0.79 2016-08-31 $641.00K $151.00K -$10.96M -$0.87
Margins and returns by year Period end Gross margin Net margin Return on equity Return on capital 2025-12-31 - - 32.07% -7.52% 2024-12-31 - - -13.11% -8.77% 2023-12-31 - 379.70% 3.12% -7.35% 2022-12-31 31.52% -1,352.61% -24.19% -26.70% 2021-08-31 - -850.50% -19.73% -20.69% 2020-08-31 - -424.76% -35.01% -35.68% 2019-08-31 96.67% -531.08% -74.02% -45.83% 2018-08-31 - -519.68% -40.91% -30.09% 2017-08-31 92.39% -426.71% -54.48% -55.99% 2016-08-31 23.56% -1,710.45% -41.86% -38.22%
Cash and debt by year Period end Cash Debt 2025-12-31 $45.95M - 2024-12-31 $54.42M - 2023-12-31 $66.77M - 2022-12-31 $40.46M $25.00K 2021-08-31 $77.25M - 2020-08-31 $22.59M - 2019-08-31 $3.33M $9.66M 2018-08-31 $5.00M $11.39M 2017-08-31 $3.97M - 2016-08-31 $3.91M -
Free cash flow by year Period end Free cash flow Stock-based compensation 2025-12-31 -$9.15M $5.99M 2024-12-31 -$8.43M $4.05M 2023-12-31 -$10.55M $4.21M 2022-12-31 -$28.41M $11.51M 2021-08-31 -$21.56M $2.69M 2020-08-31 -$12.52M $465.00K 2019-08-31 -$12.96M $808.00K 2018-08-31 -$14.66M $1.55M 2017-08-31 -$5.84M $1.57M 2016-08-31 $4.65M $634.00K
Dividend history Most recent payment Jan 16, 2026 Paid in the last twelve months $0.25 Payment date Dividend per share 2026-01-16 $0.25
Investor relations Next earnings report Next confirmed report Nov 12, 2026 Consensus EPS estimate $0.43 Past earnings dates Reported Fiscal period EPS estimate 2026-08-10 Jun 2026 $0.43 2026-05-19 Mar 2026 - 2026-03-26 Dec 2025 - 2025-11-13 Sep 2025 -$0.04 2025-08-14 Jun 2025 -$0.04 2025-05-15 Mar 2025 -$0.03 2025-03-27 Dec 2024 -$0.03 2024-11-07 Sep 2024 $0.01
Filings and sources Company website oramed.com SEC filings 10-K, 10-Q and 8-K on EDGAR Earnings calendar All upcoming reports Similar companies Vertex Pharmaceuticals Inc (VRTX) · Regeneron Pharmaceuticals, Inc. (REGN) · Moderna, Inc. (MRNA) · Incyte Corp (INCY) · Insmed Inc (INSM) · Bio-Techne Corp (TECH) · Thermo Fisher Scientific Inc. (TMO) · Danaher Corp (DHR)
All Healthcare companies
Understanding these figures
Price-to-earnings ratio · Short interest · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades